Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 5/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956687 | 0.92 | PTGES (0.41) | KDRCSNK1DCSNK1E | |
| SCHEMBL9956951 | 0.89 | RXFP1 (0.42) | KDRRXFP1CSNK1DCSNK1EPDE10A | |
| SCHEMBL9956844 | 0.86 | RXFP1 (0.43) | KDRRXFP1CSNK1DCSNK1EPDE10A | |
| SCHEMBL9955439 | 0.85 | PTGES (0.42) | KDRRXFP1CSNK1DCSNK1EPDE10A | |
| SCHEMBL9957558 | 0.83 | RBP4 (0.44) | KDRRXFP1CSNK1DCSNK1E | |
| SCHEMBL9957500 | 0.83 | RXFP1 (0.41) | KDRRXFP1CSNK1DCSNK1EPDE10A | |
| SCHEMBL9956228 | 0.82 | RBP4 (0.45) | RXFP1CSNK1DCSNK1E | |
| SCHEMBL9956302 | 0.81 | KDR (0.41) | KDRRXFP1CSNK1DCSNK1E | |
| SCHEMBL9955843 | 0.81 | WDR5 (0.40) | KDRRXFP1CSNK1DCSNK1E | |
| SCHEMBL9956979 | 0.81 | RXFP1 (0.41) | KDRRXFP1CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635578-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Hengrui (USA) Ltd. (US) | 2013-09-11 | — | — | EP | claimed |
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI (USA), LTD. | 2012-07-12 | — | — | US | claimed |
| WO-2012088411-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PAMLICO PHARMACEUTICAL INC. (US) | 2012-06-28 | — | — | WO | claimed |
| EP-2635578-B1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI USA LTD (US) | 2015-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PRXL2A, CDK2, CCNA2 | AVPR1B 2135/4885KDR 1625/4885RXFP1 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.